toxylact: a03ae02 tegaserod

The first professional lActological database in the word

Tegaserod (ATC A03AE02) is a selective serotonin 5‑HT4 receptor partial agonist used for constipation‑predominant irritable bowel syndrome (IBS‑C), but its use is restricted because of concerns about cardiovascular ischemic events and uncertainty regarding safety in breastfeeding women.medpedia.framar+3

Pharmacological profile

Tegaserod is a prokinetic agent that acts as a selective 5‑HT4 receptor partial agonist with additional weak activity at 5‑HT1 receptors. By stimulating 5‑HT4 receptors on enteric neurons, it enhances acetylcholine release, increases gastrointestinal motility, and accelerates colonic transit. Clinically, tegaserod improves IBS‑C symptoms such as abdominal pain, bloating, and constipation, particularly in women.ema.europa+5

Therapeutic indications and regulatory status

Medicines in class A03AE02 are indicated for functional bowel disorders, especially IBS with constipation and chronic idiopathic constipation. Zelnorm (tegaserod) received approval in several markets for IBS‑C in women under 55 years without significant cardiovascular disease, but marketing was suspended or refused in many regions because of safety concerns. Current access in some countries is highly restricted and limited to carefully selected patients following individualized risk–benefit assessment.pharmatimes+7

Toxicology and major safety issues

Tegaserod’s main toxicological concern is a possible association with ischemic cardiovascular events (myocardial infarction, stroke, and unstable angina) observed in pooled clinical trial data. In an analysis of more than 18,000 patients, cardiovascular ischemic events occurred in approximately 0.1% of tegaserod‑treated patients versus 0.01% of placebo‑treated patients, mostly in individuals with pre‑existing cardiovascular risk factors. As a result, regulators requested withdrawal or restricted use, and tegaserod is contraindicated in patients with a history of ischemic heart disease, cerebrovascular disease, uncontrolled hypertension, or multiple cardiovascular risk factors.rxfiles+5

Other adverse effects include headache, abdominal pain, diarrhea, and occasional hypotension or syncope, which generally are mild but may be clinically relevant in vulnerable patients. Animal toxicology has raised theoretical concerns about tumorigenicity, which contributes to caution regarding exposure during lactation and in younger populations.drugbank+5

Table: Key toxicological features of tegaserod (A03AE02)

Aspect

Data (summary)

Target receptors

Selective 5‑HT4 partial agonist; weak 5‑HT1 activitymedpedia.framar+2

Main system affected

Gastrointestinal motility and visceral sensitivitymedpedia.framar+2

Serious risk

Ischemic cardiovascular events (MI, stroke, unstable angina)pharmatimes+1

High‑risk populations

Patients with cardiovascular disease or major risk factorsema.europa+1

Regulatory consequence

Withdrawal/refusal; restricted re‑introduction in some marketsema.europa+2

Tumorigenicity concern

Potential serious reactions including tumorigenicity mentioned in labelingdrugbank+1

Use in pregnancy and lactation

Human data on tegaserod use during pregnancy are limited, and routine use is generally discouraged unless the potential benefit clearly outweighs potential fetal risk. Preclinical data show reproductive toxicity at high doses, so current product information advises against use in pregnancy when effective alternatives exist.accessdata.fda+2

No clinical data are available on tegaserod excretion into human milk or direct effects on breastfed infants. Because of the possibility of serious adverse reactions in the breastfed infant, including theoretical tumorigenic risk and the systemic cardiovascular concerns, official sources and drug information databases recommend avoiding tegaserod during breastfeeding. E‑lactancia classifies tegaserod as “quite safe / compatible in certain circumstances” based on low oral bioavailability, high protein binding, and large volume of distribution, but still notes that its market withdrawal for cardiovascular ischemia justifies a conservative approach and close monitoring if used.ncbi.nlm.nih+4

In toxicological‑lactological practice, tegaserod (A03AE02) should be considered a medicine of high caution in lactation: avoid whenever possible; if absolutely necessary, limit use to short courses in healthy, low‑risk mothers with term infants and ensure cardiovascular risk stratification and clinical follow‑up.e-lactancia+3

Clinical risk–benefit and monitoring

For women of reproductive age, especially during lactation, alternative therapies for IBS‑C and functional constipation with safer cardiovascular profiles are generally preferred. If tegaserod is prescribed, baseline cardiovascular assessment (history, blood pressure, and risk factor evaluation) and ongoing monitoring for chest pain, dyspnea, neurologic symptoms, or syncope are essential. Any sign of ischemic cardiovascular events must prompt immediate discontinuation and urgent evaluation.sciencedirect+4

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.